Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, 2145, Australia.
Hepatol Int. 2022 Oct;16(5):1032-1034. doi: 10.1007/s12072-022-10408-6. Epub 2022 Sep 7.
Asian-Pacific nations are home to more than half the world's population and similar to other global super regions, metabolic dysfunction associated fatty liver disease (MAFLD) is the principal cause for chronic liver disease. To address the challenges ahead for tackling the disease at-scale, the Asian Pacific Association for the Study of the Liver (APASL) was the first pan-national society to endorse and lead the process for redefining the disease and adopting the more appropriate term "MAFLD" with its accompanying set of positive diagnostic criteria. As with this initiative, APASL and Hepatology International will continue to strive to lead the field and work with sister societies towards full adoption of MAFLD. This will advance the science and practice of Hepatology and help incorporate MAFLD within multidisciplinary care teams. Ultimately, it will lead to more cogent clinical trials built on innovative design platforms that include patients with any disease related to metabolic dysfunction. For our patients, an outcome of these endeavours will be the provision of holistic person-centred care for this disease that is so common in our region.
亚太地区拥有世界上一半以上的人口，与其他全球超级地区类似，代谢相关脂肪性肝病（MAFLD）是导致慢性肝病的主要原因。为了应对大规模治疗该疾病的未来挑战，亚太肝脏研究学会（APASL）是第一个认可并主导重新定义该疾病并采用更合适的术语“MAFLD”及其伴随的一系列阳性诊断标准的跨国学会。与这一举措一样，APASL 和《国际肝脏病学杂志》将继续努力引领该领域，并与姐妹学会合作，全面采用 MAFLD。这将推动肝脏病学的科学和实践，并有助于将 MAFLD 纳入多学科护理团队。最终，它将导致更多基于包括代谢功能障碍相关疾病患者的创新设计平台的更有力临床试验。对于我们的患者，这些努力的结果将是为该疾病提供整体以患者为中心的护理，因为该疾病在我们地区非常普遍。
